Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02569502
A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT02569515
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Phase 2
Active, not recruiting
- Conditions
- Pancreatic CancerAdult Solid TumorLymphoma, Large-Cell, AnaplasticPrimary Brain TumorsSarcomasBreast CancerNon-Small Cell Lung CancerOvarian CancerPapillary Thyroid CancerSalivary Gland Cancers
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 534
- Registration Number
- NCT02568267
- Locations
- 🇺🇸
Dignity Health St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis
Completed
- Conditions
- Anemia
- Interventions
- Other: MIRCERA
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 144
- Registration Number
- NCT02567188
A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT02567331
A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 167
- Registration Number
- NCT02564770
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
Phase 1
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: RO7070179
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT02564614
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 63
- Registration Number
- NCT02565641
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 54
- Registration Number
- NCT02564094
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02564107
© Copyright 2025. All Rights Reserved by MedPath